OraSure Technologies CEO Carrie Eglinton Manner said in her presentation that the firm's recent $25 million acquisition of ...

Highlights from the third day included information about Quanterix's new Simoa One platform, expected to launch at the end of ...

The Dublin-based firm said that it will use the money for development for its rapid test to aid the diagnosis and treatment of sepsis.

The proteomic blood test could be a noninvasive tool used to improve detection of the condition, which currently takes an average of 7.5 years to diagnose.

The firm will use its blood-based tests to explore connections between Alzheimer's disease and neuronal α-synuclein conditions including Parkinson's disease.

Sapient will be an Alamar certified service provider for Alamar's NULISAseq Inflammation panel and its NULISAseq CNS Disease panel.

Last week, readers were most interested in a story about the progress made by test developers toward commercializing rapid tests for sepsis.

Rounding out the other four largest financing rounds in 2024 are proteomics company Alamar Biosciences' $128 million Series C ...

NEW YORK — Owlstone Medical, a UK-based developer of breath-based diagnostics, said on Wednesday that it has closed a $27 million Series E financing round.

The firm said preliminary core Q4 2024 revenues are expected to be flat, exceeding prior expectations, while its China business has stabilized and will recover.

SAN FRANCISCO — QuidelOrtho CEO Brian Blaser noted in his presentation that in 2024 the company made changes to position the firm for near- and long-term growth, including flattening the ...